Brunner, Hermine I. http://orcid.org/0000-0001-9478-2987
Wong, Robert
Nys, Marleen
Kou, Tzuyung D.
Dominique, Alyssa
Martini, Alberto
Lovell, Daniel J.
Ruperto, Nicolino
,
Funding for this research was provided by:
Bristol-Myers Squibb Company
Article History
Accepted: 9 September 2020
First Online: 8 October 2020
Declarations
:
: Studies cited in this review were funded by Bristol-Myers Squibb Company. The review was commissioned by <i>Pediatric Drugs</i> and funded by Bristol-Myers Squibb Company.
: HIB: speaker fees: Novartis and Roche; grant/research support: Bristol-Myers Squibb Company and Pfizer; consulting fees: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb Company, EMD Serono, Enzyvant, Genentech/Roche, GlaxoSmithKline, Janssen, Lilly, Novartis, R-Pharm, and UCB. RW, MN, TDK, and AD: shareholders and stakeholders of Bristol-Myers Squibb Company. AM: consulting fees from Janssen, Novartis, and Pfizer. Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia has received consulting fees from AbbVie, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, EMD Serono, Janssen, Novartis, Pfizer, and R-Pharm for the work of AM. DJL: speakers’ bureau: Bristol-Myers Squibb Company and Genentech; data and safety monitoring board: Forest Research and the National Institutes of Health-NIAMS. Cincinnati Children’s Hospital Medical Center has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb Company, Centocor, F. Hoffmann-La Roche, Genentech, Novartis, Pfizer, Regeneron, UCB, and XOMA for the work of DJL. NR: grant/research support (paid to the Istituto Giannina Gaslini Hospital): Bristol-Myers Squibb Company, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Swedish Orphan Biovitrum (Sobi) (this funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties); speaker fees/honoraria: AbbVie, Ablynx, AstraZeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eli Lilly, EMD Serono, F. Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, R-Pharma, Sanofi, Servier, Sinergie, Sobi, and Takeda.
: Not applicable.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
: HIB, AM, DJL, and NR had a pivotal and critical role in the design, implementation, analysis, and reporting of the intravenous and subcutaneous abatacept pivotal juvenile idiopathic arthritis trials. The manuscript was drafted and revised critically by the named authors.